Smarter Virus Clearance: Replacing Worst-Case Testing With Data-Driven QbD

Virus clearance studies occupy an awkward position in biologics development. They are non-negotiable for viral safety, and they are among the most expensive and least flexible studies a program will run. The result is a set of habits - conservative, condensed, worst-case - that made sense when there was no better option, and which are now quietly costing programs both time and process understanding.

The costs are structural rather than incidental.

Why virus clearance studies are hard

They are expensive, which limits how much you can learn. Studies require BSL-2 virus laboratories, substantial quantities of material, and specialized external labs with limited assay capacity. Cost per run constrains the number of runs, and a small number of runs constrains what can be concluded.

They happen late, which makes failure costly. Virus clearance studies are typically executed after process development is complete. A failure at that point means repeating studies at the worst possible moment - and can delay a program by three to nine months.

The analytics are imprecise. Cell-based virus quantification has inherently limited precision. When the measurement uncertainty is comparable to the effect being measured, resolving the contribution of an individual parameter becomes genuinely difficult.

Worst-case designs obscure causation. The standard response to limited runs is to test all parameters simultaneously at their worst-case settings. If clearance is adequate under those conditions, viral safety is demonstrated - but nothing is learned about which parameter mattered, or whether any of them interacted.

Conservative ratings over-classify. With thin data, risk assessments default to caution. Parameters are classified as potentially critical because they cannot be shown otherwise, and each classification generates controls that constrain manufacturing for the product's commercial life.

The QbD alternative

Quality by Design applied to virus clearance replaces the collective worst-case assumption with a targeted question: which parameters actually influence viral clearance, and by how much?

That reframing changes the study design. Instead of one condensed worst-case experiment answering a binary question, the program builds evidence - from designed experiments, from platform knowledge, from modeling - that resolves individual parameter contributions.

The consequences are practical:

• Studies target parameters with demonstrated impact, rather than treating every parameter as equally suspect.
• Control strategies rest on data, so tight controls are applied where they protect patients and not where they merely reflect uncertainty.
• Timelines shorten, because predictive models and prior knowledge reduce the number of expensive laboratory studies required.
• Regulatory dialogue simplifies, because a transparent scientific rationale is easier to defend than a conservative assumption.
• Success rates improve, since efficient risk coverage produces reliable studies without unnecessary complexity.

The counter-intuitive part: less testing, more safety

It is reasonable to ask whether targeted testing is a weakening of viral safety. The opposite is closer to the truth.

Worst-case testing demonstrates that clearance is adequate under one particular combination of extreme conditions. It says little about behaviour elsewhere in the operating space, and nothing about which conditions were responsible for the result. If manufacturing later drifts in a direction the study did not probe, there is no basis for predicting the consequence.

A parameter-resolved understanding supports exactly that prediction. Knowing that load density strongly affects clearance while residence time does not is more protective than knowing that a worst-case combination passed - because it tells you what to watch, and what a deviation actually means.

What it takes to get there

Three capabilities separate organizations that can work this way from those that cannot:

Structured platform knowledge. Historical data is only useful if it is contextualized and retrievable. Programs that can reference prior clearance behaviour across comparable processes start with a substantial evidence base; programs whose history sits in unstructured reports start from zero every time.

Surrogate systems. Regulators now accept alternatives to infectious model viruses in appropriate contexts - including CHO-derived endogenous virus-like particles as surrogates. Surrogates permit far more experimentation than BSL-2 infectious studies allow, which is what makes designed experiments feasible.

Modeling capability. Mechanistic models let a team explore process variability in silico before committing to laboratory work, focusing expensive studies on the questions that actually remain open.

Where this is heading

The field is entering a prolonged hybrid phase in which classical infectious-virus studies coexist with model-enabled approaches. During that phase, virus clearance capability becomes a genuine differentiator: organizations without modeling, surrogate systems or structured platform data remain fully dependent on costly external labs and their timelines.

For sponsors, the practical implication is worth stating plainly. The question to ask a partner is not whether they can run virus clearance studies - most can. It is whether they can tell you which parameters matter and why, and defend that answer to a regulator.

---

Rentschler Biopharma applies QbD principles, surrogate-spiked studies and mechanistic modeling to virus clearance. To discuss a viral safety strategy, contact our Business Development team.